Unknown PHASE2 INTERVENTIONAL 1-arm NCT03679182

Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care

A Pilot Study on Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care

Sponsor: Khon Kaen University

Conditions End Stage Cancer Nausea Vomiting

Interventions Olanzapine

Updated 5 times since 2018 Last updated: Sep 19, 2018 Started: Sep 1, 2018 Primary completion: Sep 30, 2020 Completion: Sep 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates End Stage Cancer and Nausea and is currently ongoing. Khon Kaen University leads this study, which shows 5 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Oct 2018 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Sep 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Khon Kaen University

Data source: Khon Kaen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Khon Kaen, Thailand